Sjögren's syndrome-associated interstitial lung disease: A multicenter study

Reina, Dèlia; Vilaseca, Daniel Roig; Torrente-Segarra, Vicenç; Cerdá, Dacia; Castellví, Iván; Torné, C. Díaz; Moreno, Mireia; Narváez, Javier; Ortiz, Vera; Blavia, Rosana; Martı́n-Baranera, Montserrat; Corominas, H.

doi:10.1016/j.reumae.2015.09.009

Cited by 8 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Varied pulmonary manifestations were reported as extraglandular complications, depending on the detection methods and patient selection (3)(4)(5). High resolution computed tomography (HRCT) is a useful tool to detect lung involvement.…”

Section: Original Articlementioning

confidence: 99%

Risk factors for primary Sjögren syndrome-associated interstitial lung disease

et al. 2018

View full text Add to dashboard Cite

Section: Original Articlementioning

confidence: 99%

Risk factors for primary Sjögren syndrome-associated interstitial lung disease

et al. 2018

View full text Add to dashboard Cite

“…In the study from Reina et al, 25 patients with pSS-ILD were more likely to be positive for anti-SSA antibodies. Nevertheless, in 60% of the patients, the diagnosis of ILD preceded that of pSS (23). Conversely, Roca et al reported that only 5 (24%) out of 21 patients were diagnosed with ILD prior to the diagnosis of pSS (24).…”

Section: N Cutaneous Involvementmentioning

confidence: 97%

“…Overall, in 84% of patients pSS-ILD was either stable over time or worsening, while older age was associated with ILD deterioration. Therefore higher rates of mortality and morbidity in PSS are most likely related to ILD (23). Amyloidosis, granulomatous lung disease, pulmonary lymphoma, cystic lung disease, pseudolymphoma and pulmonary arterial hypertension have been also described but with lower frequency in pSS.…”

Section: N Cutaneous Involvementmentioning

confidence: 99%

The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands

et al. 2017

View full text Add to dashboard Cite

SUMMARYAlthough primary Sjögren's syndrome (pSS) is a mild indolent chronic disease mainly characterized by mucosal dryness in the majority of cases, a consistent subgroup of patients display extra-glandular manifestations. Virtually any organs and systems can be affected, leading to a more serious disease prognosis. Therefore, the prompt identification of patients at higher risk of extra-glandular manifestations is necessary to start a thorough follow up and an aggressive treatment. The aim of this review article is to provide an overview of epidemiological, clinical and serological features of extra-glandular manifestations in pSS as well as current knowledge about putative biomarkers useful in clinical practice. Key words:Sjögren's syndrome; Extra-glandular manifestations; Cardiovascular risk. Reumatismo, 2017; 69 (3): 93-100 n INTRODUCION P rimary Sjögren's syndrome (pSS) is a complex and heterogeneous chronic autoimmune disease primarily characterized by a focal lymphocytic chronic inflammation of exocrine glands leading to progressive loss of secretory function (1). Therefore, the specific case-history of pSS is dominated by signs and symptoms of mucosal dryness. However, although salivary and lachrymal glands represent the main target of pSS, several other organs and systems may be affected during the disease course in at least one third of patients, resulting in a plethora of systemic clinical manifestations, serological abnormalities and complications (2). The most severe complication of pSS is non-Hodgkin lymphoma occurring in about 5% of patients (3) and dramatically worsening disease prognosis. In this regard, the prompt identification of pSS patients with higher risk of developing extraglandular manifestations is mandatory for correct management. Low C3 and C4 levels, cryoglobulins, monoclonal component, anti-Ro/ SSA, anti-La/SSB, rheumatoid factor and hypergammaglobulinaemia represent poor prognostic serological factors in pSS associated with lymphoma and severe extraglandular features (2). Furthermore, histological features such as the presence of germinal centre-like structures in the minor salivary glands have been associated with higher risk of developing lymphoma (4). The purpose of this review article is to discuss current knowledge of extra-glandular manifestations in pSS not secondary to mucosal dryness, excluding pathogenesis and clinical manifestations of lymphoproliferative disorders. n MUSCULOSKELETAL INVOLVEMENTMusculoskeletal manifestations such as myalgia, arthralgia and morning stiffness are present in as many as 90% of patients, while clinically evident arthritis is found in up to 17%. In a recent study conducted on 17 female patients with pSS and 18 patients with secondary SS (sSS), ultrasonography (US) was used to confirm the non-erosive nature of joint involvement in pSS and to discriminate between pSS and RA-associated SS. Synovitis was commonly detected in pSS, mainly in metacarpophalangeal joints (MCP), wrists, and knees. Bone erosions also may occur. Power Doppler signal ...

show abstract

“…Interstitial lung disease (ILD) is also a very common symptom of patients with pSS. The prevalence of ILD in patients with pSS is ∼5–35% 2. The EULAR Sjögren's syndrome disease activity index is a clinical index designed to measure disease activity in patients with pSS 3…”

mentioning

confidence: 99%

Elevated Il-37, Il-18 and Il-18Bp Serum Concentrations in Patients with Primary SjöGren'S Syndrome

Wang

Xia

Shen

et al. 2017

Journal of Investigative Medicine

View full text Add to dashboard Cite

The objectives of this study were to examine the serum levels of interleukin (IL)-37 and its clinical association in patients with primary Sjögren's syndrome (pSS) and to investigate whether or not IL-37 participates in the regulation of the pathogenesis of pSS. ELISA was used to analyse the serum levels of IL-37, total IL-18 and IL-18 binding protein (IL-18BP). The level of free IL-18 was calculated based on the mass action law. The correlations between the IL-37 serum levels with the laboratory values and the total IL-18 and IL-18BP serum levels were analyzed by a Spearman's correlation test. The serum levels of IL-37 in the patients with pSS were significantly increased compared with the healthy controls (HCs). The levels were especially elevated in the patients with pSS with positive anti-Ro/SSA and/or anti-La/SSB antibodies. Furthermore, the patients with pSS showed high serum levels of total IL-18, free IL-18 and IL-18BP compared with the HCs. Strikingly, the IL-37 levels were significantly positively correlated with the antibody levels in the patients with pSS, including rheumatoid factor, anti-Ro/SSA, and anti-La/SSB and the total IL-18 and IL-18BP serum levels. The serum levels of IL-37, which were correlated with antibody production and the serum levels of total IL-18 and IL-18BP, were elevated in the patients with pSS. IL-37, an important anti-inflammatory cytokine, may participate in the regulation of the pathogenesis of pSS.

show abstract

Sjögren's syndrome-associated interstitial lung disease: A multicenter study

Cited by 8 publications

References 17 publications

Risk factors for primary Sjögren syndrome-associated interstitial lung disease

Risk factors for primary Sjögren syndrome-associated interstitial lung disease

The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands

Elevated Il-37, Il-18 and Il-18Bp Serum Concentrations in Patients with Primary SjöGren'S Syndrome

Contact Info

Product

Resources

About